More than 15% of radiotherapy clinics fail external audits with anthropomorphic phantoms conducted by Imaging and Radiation Oncology Core-Houston (IROC-H) while passing other industry-standard quality assurance (QA) tests. We seek to evaluate the predicted impact of such failed plans on outcomes for patients treated with stereotactic body radiation therapy (SBRT) for lung tumors. We conducted a retrospective study of 55 patients treated with SBRT for lung tumors with prescription BED10 ≥100Gy using a treatment planning system (TPS) that passed IROC-H phantom audits. Sample linac beam models with introduced errors were commissioned by varying the multi-leaf collimator leaf tip offset parameter (i.e., 'dosimetric leaf gap') over the range +/-1.0 mm relative to the validated model. These models mimic TPS that pass internal QA measures but fail IROC-H tests. Patient plans were recalculated on sample beam models. Predicted tumor control probability (TCP) and normal tissue complication probability (NTCP) were calculated based on published dose-response models. A leaf tip offset value of -1.0 mm decreased the fraction of plans receiving a PTV BED10 ≥100 Gy from 95% to 27%. This translated to a significant decrease in 2-yr TCP of 4.8% (95% CI: 2.0-5.5%) with a decrease in TCP up to 21%. Conversely, leaf tip offset of +1.0 mm resulted in 36% of patients exceeding previously met OAR constraints, including two instances of spinal cord and brachial plexus overdoses and a small increase in chest wall NTCP by 0.7%, (95% CI 0.5%-0.8%). Simulated treatment plans with modest MLC leaf offsets result in lung SBRT plans that significantly under-dose tumor or exceed OAR constraints. These dosimetric endpoints translate to significant detriments in TCP. These simulated plans mimic planning systems that pass internal QA measures but fail independent phantom-based tests, underscoring the need for enhanced quality assurance including external audits of TPS.
Read full abstract